Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 May 10;336(7652):1062-6.
doi: 10.1136/bmj.39547.603218.AE.

Medical management of Crohn's disease

J R Fraser Cummings  1 , Satish Keshav, Simon P L Travis
Affiliations
Review

Medical management of Crohn's disease

J R Fraser Cummings et al. BMJ. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: JRFC has received educational grant support from the drug companies Abbot, Shire, and Ferring and research support and lecturing fees from Asahi. SK has consulted for ChemoCentryx, Ferring, and Procter & Gamble Pharmaceuticals and received lecture fees from Abbott, Procter & Gamble Pharmaceuticals, and Schering-Plough. SPLT has received unrestricted educational grant support or research funding from Bristol-Myers Squibb, Procter & Gamble Pharmaceuticals, Schering Plough, and UCB Pharma and consulting or lecture fees from Abbott, Asahi, Centocor, Elan, Ferring, Ocera, Otsuka, and Shire.

Figures

None
Step-up versus top-down therapy. A recent study has challenged our approach to the management of newly diagnosed patients with the disease by examining early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease in the hope of changing the long term course of the disease. It is too early to say if this objective has been achieved
See this image and copyright information in PMC

References

    1. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17. - PubMed
    1. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004;53:1471-8. - PMC - PubMed
    1. Travis SP, Stange EF, for the European Crohn’s and Colitis Organisation (ECCO). European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 2006;55(suppl 1):i1-58. - PMC - PubMed
    1. Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007;133:312-39. - PubMed
    1. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease. Cochrane Database Syst Rev 2005;(1):CD003715. - PubMed

MeSH terms